Baseline disease characteristics in the randomized and 5-year completers cohorts. Statistics are group means except where noted.
| Characteristic | Randomized Cohort* | 5-Year Completers Cohort by Original Randomization Arm | ||||
|---|---|---|---|---|---|---|
| ADA+MTX, n = 268 | ADA, n = 274 | MTX, n = 257 | ADA+MTX, n = 124 | ADA, n = 115 | MTX, n = 115 | |
| RA duration, yrs | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 |
| SJC (66) | 21.1 | 21.8 | 22.1 | 21.1 | 21.0 | 22.9 |
| TJC (68) | 30.7 | 31.8 | 32.3 | 30.7 | 32.8 | 31.6 |
| DAS28 | 6.3 | 6.4 | 6.3 | 6.3 | 6.3 | 6.2 |
| HAQ | 1.5 | 1.6 | 1.5 | 1.4 | 1.6 | 1.5 |
| CRP, mg/dl | 3.9 | 4.1 | 4.0 | 3.9 | 3.7 | 3.7 |
| mTSS | 18.1 | 18.8 | 21.9 | 15.5 | 16.8 | 19.5 |
| JE | 11.0 | 11.3 | 13.6 | 9.4 | 9.7 | 10.7 |
| JSN | 7.1 | 7.5 | 8.2 | 6.1 | 7.1 | 8.8 |
| Estimated annual mTSS progression, median† | 28.5 | 29.6 | 25.6 | 24.0 | 23.9 | 21.9 |
↵* Data from Breedveld, et al11 except for “estimated annual mTSS progression.”
↵† Median of the estimated individual patient annual mTSS progression. ADA: adalimumab; DAS28: 28-joint Disease Activity Score; HAQ: Health Assessment Questionnaire; JE: joint erosions; JSN: joint space narrowing; mTSS: modified total Sharp score; MTX: methotrexate; SJC: swollen joint count; TJC: tender joint count.